TY - JOUR
T1 - Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors
AU - Grisanti, Salvatore
AU - Filice, Angelina
AU - Basile, Vittoria
AU - Cosentini, Deborah
AU - Rapa, Ida
AU - Albano, Domenico
AU - Morandi, Alessandra
AU - Laganà, Marta
AU - Dalla Volta, Alberto
AU - Bertagna, Francesco
AU - Tiberio, Guido M.A.
AU - Volante, Marco
AU - Terzolo, Massimo
AU - Versari, Annibale
AU - Berruti, Alfredo
N1 - Funding Information:
was supported in part by a grant from FIRM (Fondazione Internazionale di Ricerca in Medicina), Cremona, Italy and AIRC (Associazione Italiana per la Ricerca contro il Cancro) grant no. IG14411 PI: Alfredo Berruti.
Publisher Copyright:
© 2019 Endocrine Society 2019.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/1/8
Y1 - 2020/1/8
N2 - Context: We investigated the role of Gallium 68 dodecanetetraacetic acid Tyr3-octreotide (68Ga-DOTATOC) positron emission tomography/computed tomography (PET/CT) in detecting somatostatin receptors (SSTRs) in 19 patients with metastatic adrenocortical carcinoma (ACC) and explored the activity of yttrium-90/lutetium-177 (90Y/177Lu-DOTATOC) peptide receptor radionuclide therapy (PRRT). Case description and methods: 68Ga uptake in metastatic sites was scored in terms of intensity and anatomical uptake distribution of standard uptake value (SUV). Tissue expression of SSTR2A and SSTR5 was also evaluated by immunohistochemistry (IHC) on primary tumors. Eight (42%) patients displayed radiometabolic uptake of any-grade intensity with focal and limited distribution. Two (11%) patients displayed strong uptake in multiple lesions and were treated with PRRT. Both obtained an overall disease control lasting 4 and 12 months, respectively. Conclusions: ACC can express SSTRs as detected by IHC and 68Ga-DOTATOC PET. SSTRs-based PRRT may represent a potential treatment opportunity for a minority of patients with advanced ACC. This treatment modality deserves further investigation.
AB - Context: We investigated the role of Gallium 68 dodecanetetraacetic acid Tyr3-octreotide (68Ga-DOTATOC) positron emission tomography/computed tomography (PET/CT) in detecting somatostatin receptors (SSTRs) in 19 patients with metastatic adrenocortical carcinoma (ACC) and explored the activity of yttrium-90/lutetium-177 (90Y/177Lu-DOTATOC) peptide receptor radionuclide therapy (PRRT). Case description and methods: 68Ga uptake in metastatic sites was scored in terms of intensity and anatomical uptake distribution of standard uptake value (SUV). Tissue expression of SSTR2A and SSTR5 was also evaluated by immunohistochemistry (IHC) on primary tumors. Eight (42%) patients displayed radiometabolic uptake of any-grade intensity with focal and limited distribution. Two (11%) patients displayed strong uptake in multiple lesions and were treated with PRRT. Both obtained an overall disease control lasting 4 and 12 months, respectively. Conclusions: ACC can express SSTRs as detected by IHC and 68Ga-DOTATOC PET. SSTRs-based PRRT may represent a potential treatment opportunity for a minority of patients with advanced ACC. This treatment modality deserves further investigation.
UR - http://www.scopus.com/inward/record.url?scp=85081075980&partnerID=8YFLogxK
U2 - 10.1210/clinem/dgz091
DO - 10.1210/clinem/dgz091
M3 - Journal articles
C2 - 31633759
AN - SCOPUS:85081075980
SN - 0021-972X
VL - 105
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 3
M1 - dgz091
ER -
